AI Article Synopsis
- Sepsis leads to specific immune system changes, particularly the increase of myeloid-derived suppressor cells (MDSCs), which help control inflammation but can linger in those with ongoing critical illness.
- The study employs advanced techniques like Cellular Indexing of Transcriptomes and Epitopes by Sequencing to analyze MDSC types based on gene expression and biological functions.
- Findings reveal a new lineage and differentiation pathway for MDSCs following sepsis, emphasizing their variable responses related to patient outcomes and demonstrating their ability to change, contradicting the previous belief of a fixed lineage.
Article Abstract
Introduction: Sepsis engenders distinct host immunologic changes that include the expansion of myeloid-derived suppressor cells (MDSCs). These cells play a physiologic role in tempering acute inflammatory responses but can persist in patients who develop chronic critical illness.
Methods: Cellular Indexing of Transcriptomes and Epitopes by Sequencing and transcriptomic analysis are used to describe MDSC subpopulations based on differential gene expression, RNA velocities, and biologic process clustering.
Results: We identify a unique lineage and differentiation pathway for MDSCs after sepsis and describe a novel MDSC subpopulation. Additionally, we report that the heterogeneous response of the myeloid compartment of blood to sepsis is dependent on clinical outcome.
Discussion: The origins and lineage of these MDSC subpopulations were previously assumed to be discrete and unidirectional; however, these cells exhibit a dynamic phenotype with considerable plasticity.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11076668 | PMC |
| http://dx.doi.org/10.3389/fimmu.2024.1355405 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myeloid Cell Mobilization and Recruitment by Human Mesothelioma in NSG-SGM3 Mice.
Cells
December 2024
Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Malignant pleural mesothelioma is a neoplasm that is often detected late due to nonspecific symptoms. This study utilized NSG-SGM3 mice to examine interactions between a human-derived mesothelioma reporter cell line (MZT-Luc2-mCherry) and the host's myeloid compartment. Tumor growth was assessed using optical tomography, while cytokine/chemokine production was analyzed via multiplex assay.
View Article and Find Full Text PDFGenome-wide CRISPR-Cas 9 screens identify BCL family members as modulators of response to regorafenib in experimental glioma.
Neuro Oncol
January 2025
Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen; Tübingen, Germany.
Background: Registered systemic treatment options for glioblastoma patients are limited. The phase II REGOMA trial suggested an improvement of median overall survival in progressive glioblastoma by the multi-tyrosine kinase inhibitor regorafenib. This has not been confirmed by GBM AGILE.
View Article and Find Full Text PDFRemodelling of the immune landscape by IFNγ counteracts IFNγ-dependent tumour escape in mouse tumour models.
Nat Commun
January 2025
The Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK.
Loss of IFNγ-sensitivity by tumours is thought to be a mechanism enabling evasion, but recent studies suggest that IFNγ-resistant tumours can be sensitised for immunotherapy, yet the underlying mechanism remains unclear. Here, we show that IFNγ receptor-deficient B16-F10 mouse melanoma tumours are controlled as efficiently as WT tumours despite their lower MHC class I expression. Mechanistically, IFNγ receptor deletion in B16-F10 tumours increases IFNγ availability, triggering a remodelling of the immune landscape characterised by inflammatory monocyte infiltration and the generation of 'mono-macs'.
View Article and Find Full Text PDFCXCR4-directed endoradiotherapy with [Lu]Pentixather added to total body irradiation for myeloablative conditioning in patients with relapsed/refractory acute myeloid leukemia.
Theranostics
January 2025
Department of Internal Medicine III, School of Medicine and Health, Technical University of Munich, Munich, Germany.
Article Synopsis
- Despite improvements in targeted therapy for Acute Myeloid Leukemia (AML), the prognosis remains poor, particularly for patients with relapsed or refractory disease.
- Allogeneic hematopoietic stem cell transplantation (alloSCT) is the main curative option for high-risk patients, but the best conditioning approach is still uncertain for those who are chemotherapy-refractory.
- A study on seven AML patients who received CXCR4-directed endoradiotherapy (ERT) combined with total body irradiation and chemotherapy prior to alloSCT showed promising outcomes, with 6 out of 7 patients achieving response and successful engraftment, offering insights into a potentially effective treatment strategy for advanced cases.
Regulatory T cell therapy is associated with distinct immune regulatory lymphocytic infiltrates in kidney transplants.
Med
December 2024
Nuffield Department of Surgical Sciences, University of Oxford, Oxford OX3 9DU, UK. Electronic address:
Background: Adoptive transfer of autologous regulatory T cells (Tregs) is a promising therapeutic strategy aimed at enabling immunosuppression minimization following kidney transplantation. In our phase 1 clinical trial of Treg therapy in living donor renal transplantation, the ONE Study (ClinicalTrials.gov: NCT02129881), we observed focal lymphocytic infiltrates in protocol kidney transplant biopsies that are not regularly seen in biopsies of patients receiving standard immunosuppression.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!